Navigation Links
Products containing specific probes for detecting alternative splice forms protected

ExonHit Therapeutics, today announced the grant of a major patent, US # 6,881,571, by the United States Patent and Trademark Office on microarray products allowing the specific detection of mRNAs produced by alternative splicing, covering microarrays optimised for the discovery of alternative RNA splicing events. The patent protects the probe configuration of a unique set of five oligonucleotides for the detection of each splice variant. There are many applications for this patent, including drug discovery, diagnostics, and compound screenings for efficacy or toxicity as well as screening patients for potential efficacy of therapeutics.

Alternative RNA Splicing is a critical step in the expression of most genes, which can result in the expression of several mRNAs encoding proteins with different functions from a single gene. Splicing events are implicated in numerous pathologies and can be altered by various stress events such as virus, toxic agents, and drug exposure.

The genome-wide patented probe configuration described in the patent is the basis for the microarrays in ExonHit's SpliceArray product line launched earlier this year. The genome profiling market is rapidly growing, and SpliceArrays are the only commercially available microarrays designed to detect alternative splicing. Current SpliceArray products include GPCR, Ion Channel, and Nuclear Receptor family SpliceArrays, as well as custom design services. An Apoptosis and Cytokine gene family array will be launched in the coming months. SpliceArrays are manufactured for ExonHit by Agilent Technologies.

The granting of this patent solidifies ExonHit's leadership in the field of expression profiling and positions the company as the only partner for the conception or use of gene profiling microarrays that include alternative RNA splicing. "The granting of these claims build on the company's core assets further expanding our IP position in the field of gene expression and profiling," sta ted Bruno Tocque, President and CEO, ExonHit Therapeutics. "This is a significant event for ExonHit as we have been quite successful in leveraging strategic assets in multiple arenas, including the therapeutic, diagnostic and research tool markets ?areas in which these claims will further increase our market share."


'"/>

Source:ExonHit


Related biology news :

1. Metal-containing compounds show promise as HIV weapon
2. Preventing a pandemic: Study suggests strategies for containing a flu outbreak
3. Rapid response was crucial to containing the 1918 flu pandemic
4. Scientists generate patient-specific stem cells, Science study says
5. Identification of specific genes predicts which patients will respond to Hepatitis C treatment
6. Eating, body weight regulated by specific neurons
7. Tool developed to silence genes in specific tissues using RNAi
8. Gene-specific Ebola therapies protect non-human primates from lethal disease
9. Unique dual target specificity of kinase inhibitor key for success against cancer
10. Serotonin, acting in a specific brain region, promotes sleep in fruit flies
11. A new male-specific gene in algae unveils an origin of male and female
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ( ... online age and identity verification solutions, announced today they ... Conference 2017, May 15 thru May 17, 2017, in ... and International Trade Center. Identity impacts ... and in today,s quickly evolving digital world, defining identity ...
(Date:5/6/2017)... May 5, 2017 RAM Group ... a new breakthrough in biometric authentication based on ... mechanical properties to perform biometric authentication. These new sensors ... material created by Ram Group and its partners. This ... transportation, supply chains and security. Ram Group is ...
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... with the addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s ... hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical ...
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed for ... complexity. Named in honor of pioneering researcher Rosalind Franklin, who made a ...
(Date:10/11/2017)... LINDA, CA (PRWEB) , ... October 11, 2017 ... ... to upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding ... (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... set to take place on 7th and 8th June 2018 in San Francisco, CA. ... policy influencers as well as several distinguished CEOs, board directors and government officials from ...
Breaking Biology Technology: